Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 30,000 stock options as inducement awards to two newly hired employees under its 2021 Inducement Plan, with a grant date of December 1, 2025.

The options have an exercise price of $2.69 per share (equal to the closing price on the grant date) and vest over four years: 25% at the one-year anniversary and the remainder in 36 equal monthly installments. Awards are subject to continuous service and standard plan terms and were made in accordance with Nasdaq Listing Rule 5635(c)(4).

MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 30,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new employees. 

The Options have a grant date of December 1, 2025, and an exercise price of $2.69 per share, which is equal to the closing price of Milestone’s common shares on the grant date. The shares subject to the Options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter.

The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.

The foregoing equity award was granted as an inducement material to the employee entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individual’s entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:
Kevin Gardner kgardner@lifesciadvisors.com

FAQ

What did Milestone Pharmaceuticals (MIST) announce on December 2, 2025?

Milestone announced it granted 30,000 stock options as inducement awards to two new hires, with a grant date of Dec 1, 2025.

What is the exercise price of the MIST inducement options granted Dec 1, 2025?

The options have an exercise price of $2.69 per share, equal to Milestone’s closing price on the grant date.

How do the MIST options granted under the 2021 Inducement Plan vest?

Options vest over four years: 25% after one year, then the balance in 36 equal monthly installments, subject to continuous service.

Why did Milestone use the 2021 Inducement Plan for the MIST options?

The Plan is used to grant equity to individuals not previously employees (or after bona fide non‑employment) as a material inducement under Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement options from Milestone (MIST)?

The company granted the 30,000 options as a material inducement to the hiring of two new employees.

Are the MIST option awards conditional on continued employment?

Yes; the awards are subject to the award holder’s continuous service through each vesting date and the Plan’s standard grant terms.